QMIIZ ODT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for QMIIZ ODT (QMIIZ ODT).
QMIIZ ODT is a centrally acting alpha-2 adrenergic agonist that modulates norepinephrine release by binding to presynaptic alpha-2 adrenergic receptors, reducing sympathetic outflow from the brainstem and lowering blood pressure.
| Metabolism | Metabolized primarily in the liver by CYP1A2, CYP2D6, and CYP3A4 isoenzymes. |
| Excretion | Primarily renal (90% as unchanged drug in urine), with minor fecal excretion (<5% as metabolites). |
| Half-life | Terminal elimination half-life is 10–12 hours in healthy adults, allowing once-daily dosing. |
| Protein binding | Approximately 95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is 0.8–1.2 L/kg, indicating extensive extravascular distribution. |
| Bioavailability | Oral bioavailability is 50–70% due to first-pass metabolism; taken sublingually for faster absorption. |
| Onset of Action | Oral: therapeutic effect begins within 1–2 hours after administration. |
| Duration of Action | Duration of action is approximately 24 hours, supporting once-daily dosing for chronic therapy. |
20 mg sublingually once daily in the morning.
| Dosage form | TABLET, ORALLY DISINTEGRATING |
| Renal impairment | No dose adjustment necessary for GFR ≥30 mL/min. Use with caution in GFR <30 mL/min, maximum dose 10 mg once daily. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: maximum 10 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | Start at 10 mg once daily; titrate cautiously to 20 mg as tolerated. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for QMIIZ ODT (QMIIZ ODT).
| Breastfeeding | Unknown if QMIIZ ODT is excreted in human milk. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 4 weeks after the last dose. No M/P ratio available. |
| Teratogenic Risk | QMIIZ ODT is contraindicated in pregnancy. First trimester: high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and orofacial clefts. Second and third trimesters: risk of fetal growth restriction, premature labor, and neonatal toxicity. Pregnancy must be excluded before initiation, and effective contraception must be used during treatment. |
■ FDA Black Box Warning
No black box warning has been issued by the FDA for QMIIZ ODT.
| Serious Effects |
["Hypersensitivity to clonidine or any component of the formulation.","Bradycardia or heart block (second- or third-degree) without a pacemaker."]
| Precautions | ["Should not be used in patients with bradycardia or heart block without a pacemaker.","May cause rebound hypertension if discontinued abruptly.","Can cause sedation and dizziness, impairing ability to drive or operate machinery.","Use with caution in patients with renal impairment."] |
Loading safety data…
| Fetal Monitoring | Monitor for fetal development via ultrasound and fetal echocardiography; assess for signs of premature labor and fetal growth restriction. Monitor maternal hepatic function, thyroid function, and complete blood count monthly. Obtain baseline and periodic electrocardiograms. |
| Fertility Effects | In animal studies, QMIIZ ODT impaired fertility in both sexes. In females, it caused ovarian dysfunction and prolonged estrous cycles. In males, it reduced sperm motility and count. These effects may be reversible upon discontinuation. Advise patients of potential impact on fertility. |